ClinicalTrials.gg
CompletedNCT07113431Updated Dec 9, 2025

Partial-enteral Nutrition Protocol for Crohn's Disease

An interventional study of IBD-AID diet combined with Kate Farms Peptide 1.5 and IBD-AID diet in Crohn's Disease(CD), sponsored by Kate Farms Inc. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by Kate Farms Inc · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled Aug 2023, registered Jul 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A novel dietary intervention combining a standardized IBD diet (IBD-AID) with supplementation from a pea protein plant-based oral nutrition supplement (ONS) (Kate Farms Peptide 1.5) to improve protein, calorie, and nutrient intake in adult patients experiencing a Crohn's disease flare starting new immunologic therapy. Additionally, this study will include objective measures of body composition to improve nutrition status assessment and provide a more sensitive measure of intervention efficacy compared to anthropometric measures of body weight or BMI.

02

Conditions studied

  • Crohn's Disease(CD)
03

In context

Lead sponsor

Kate Farms Inc is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Moderate to severe CD as defined by physician and starting new biologic therapy
  • Able and willing to complete the study procedures
  • Age > 18
  • Able to comply with study measures in the opinion of the investigator

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of short bowel syndrome
  • Presence of ileostomy or colostomy
  • Presence of a pacemaker or any electronic implantable device
  • Use of pre or probiotic supplements within 14 days of randomization
  • High risk for development of refeeding syndrome
  • In the opinion of the investigator would not complete the study procedures
  • Patients with active implanted medical devices, e.g. cardiac pacemakers, defibrillators or patients connected to electronic life support devices
  • Pregnant Patients: while the use of bioimpedance technology in pregnant patients has been shown to have no adverse effects, it has yet to be clinically validated for use with that population group
  • Serious, concomitant illness that, in the opinion of the investigator would interfere with evaluation of safety or efficacy, or put the participant at risk of harm from study participation
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Placebo comparator
    IBD-AID diet

    Other: IBD-AID diet

  • Active comparator
    IBD-AID Diet + Kate Farms Peptide 1.5

    Dietary Supplement: IBD-AID diet combined with Kate Farms Peptide 1.5

Interventions

  • Dietary supplementIBD-AID diet combined with Kate Farms Peptide 1.5

    Combining standardized-IBD diet developed by the University of Minnesota (IBD-AID) with commercially available pea protein plant-based enteral nutrition formula (Kate Farms Peptide 1.5)

  • OtherIBD-AID diet

    Standardized IBD diet developed by the University of Massachusetts Medical School (IBD-AID)

06

What researchers measure

Primary outcomes

  1. Nutrient intake

    Nutrient intake improvement assessed by 24-hour dietary recall from a combined intervention of a standard IBD-AID diet with an oral nutrition supplement drink (Kate Farms Peptide 1.5) compared to a standard diet alone without an oral nutrition supplement drink.

    Time frame: 8 weeks

Secondary outcomes

  1. Body composition

    Body composition measures assessed by bioimpedance spectroscopy (BIS).

    Time frame: 8 weeks

07

Study locations

1 site
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Oct 2025, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2025
First posted
Aug 8, 2025
StartActual
Aug 1, 2023
Primary completionActual
Oct 24, 2025
CompletionActual
Oct 24, 2025
Last update
Dec 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07113431
Lead sponsor
Kate Farms Inc
Responsible party
Sponsor
First posted
Aug 8, 2025
Start date
Aug 1, 2023
Primary completion
Oct 24, 2025
Completion
Oct 24, 2025
Last update
Dec 9, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion